Recently, it has been discovered that in the human brain there are specific receptors for cannabinoids and that our body produces a substance (anandamide), able to interact with these receptors. This has allowed us to discover the existence of a true and proper "system endogenous cannabinoid", whose role within the organism is not yet entirely clear, but the study will allow us to understand the mechanisms that are at the base of the curative properties of cannabinoids. One of the main pharmacological actions of thc on the brain is to reduce the sensitivity to pain. This is very useful as an analgesic in respect of disorders such as migraine applicant or menstrual pain. Especially in the latter case the THC is suitable since it also has a function muscle relaxant, i.e. relax the muscles. In addition, the THC has an antiinflammatory action, then, is also useful in other types of pain such as those due to rheumatism. The muscle spasms are abnormal contractions of the muscles of the body, often due to serious diseases such as multiple sclerosis or Parkinson's disease. Cannabinoids have on the muscles a muscle relaxant and antispasmodic, consequently help decontrarre muscles, as demonstrated by a study published recently on the science journal 'Nature'. These specific curative properties you explain why the receptors for the cannabinoid CB1 are concentrated in the basal ganglia and cerebellum, i.e. in areas of the brain related to motor functions. Also for this reason, the Royal Pharmaceutical Society, an English association, has recently had the authorization by the British Government to proceed with further experimentation on 2000 sick people with multiple sclerosis, in order to be able to find the pharmaceutical formulation best to combat this serious disorder. In fact, one of the main issues to be solved for pharmaceutical administration of cannabis is just find the formulation more suitable for every type of disorder that is looking for a cure. In the case of muscle spasms, the road more followed from the scientific point of view is that of the aerosol. The cannabinoli also have a bronchodilatory effect, i.e. help to dilate the bronchi and facilitating breathing. This property could be exploited by those who suffer from asthma, but research is still working on a pharmaceutical formulation which allows a mode of administration is different from the smoke because the latter would damage however the lungs. Glaucoma is a serious disturbance of the view is characterized by increased intraocular pressure, i.e. the inside of the eyes. For this disease the delta-9-THC seems to be useful as, in some cases, manages to reduce the internal pressure. To discover what was a US citizen, Dr Randall which has obtained by law to be able to cure with cannabis derivatives, opening the way to this therapy for this specific disorder of the view. His choice, in fact, has also confirmed in subsequent clinical studies. Already since 1985 the FDA (Food and Drug Administration), i.e. the American organization that controls the medicinal products in the USA has permitted the sale of a synthetic cannabinoid, i.e. produced in the laboratory, the dronabinol, able to counteract the nausea in who is subjected to chemotherapy. Recent studies have shown that a synthetic cannabinoid, dronabinol, even manages to whet the appetite, producing a significant weight gain in people with AIDS and affected by the so-called syndrome of decay. It was also presented a study that has clarified that the cannabis derivatives do not interfere with the antiviral drugs, i.e. those medicinal products used for fighting viruses such as HIV, which causes AIDS. The cannabidiol, i.e. a nonpsychoactive cannabinoid, also seems to have anticonvulsionanti properties, i.e. that help to combat the convulsions, one of the most common symptoms of epilepsy. Studies carried out on this disease, however, are still at the experimental stage, even if many patients who have voluntarily subjected to experiments, argue that the cannabidiol has helped them to overcome more easily the convulsions. This is also why the British medical association, one of the British authorities more authoritative in the health field, has recently recommended to further research on the action of this substance. The morbus Alzehimer, that of Parkinson, Huntington's Chorea, are all diseases as defined neurodegenerative diseases because they are caused by a degeneration of nerve cells. Recent studies conducted by international researchers have discovered that the cannabidiol, a component not psicoattivo of cannabis, helps protect the brain cells. The research, published in the scientific journal "Proceedings of National Academy", has demonstrated that the cannabidiol acts as an antioxidant, i.e. combats aging and death of neurons. Even if the studies are always at the experimental stage this discovery opens up new possibilities in the treatment of stroke and neurodegenerative disorders. The legislation in Italy and in the world adjusts the cannabis Recently, it has been discovered that in the human brain there are specific receptors for cannabinoids and that our body produces a substance (anandamide), able to interact with these receptors. This has allowed us to discover the existence of a true and proper "system endogenous cannabinoid", whose role within the organism is not yet entirely clear, but the study will allow us to understand the mechanisms that are at the base of the curative properties of cannabinoids. One of the main pharmacological actions of thc on the brain is to reduce the sensitivity to pain. This is very useful as an analgesic in respect of disorders such as migraine applicant or menstrual pain. Especially in the latter case the THC is suitable since it also has a function muscle relaxant, i.e. relax the muscles. In addition, the THC has an antiinflammatory action, then, is also useful in other types of pain such as those due to rheumatism. The muscle spasms are abnormal contractions of the muscles of the body, often due to serious diseases such as multiple sclerosis or Parkinson's disease. Cannabinoids have on the muscles a muscle relaxant and antispasmodic, consequently help decontrarre muscles, as demonstrated by a study published recently on the science journal 'Nature'. These specific curative properties you explain why the receptors for the cannabinoid CB1 are concentrated in the basal ganglia and cerebellum, i.e. in areas of the brain related to motor functions. Also for this reason, the Royal Pharmaceutical Society, an English association, has recently had the authorization by the British Government to proceed with further experimentation on 2000 sick people with multiple sclerosis, in order to be able to find the pharmaceutical formulation best to combat this serious disorder. In fact, one of the main issues to be solved for pharmaceutical administration of cannabis is just find the formulation more suitable for every type of disorder that is looking for a cure. In the case of muscle spasms, the road more followed from the scientific point of view is that of the aerosol. The cannabinoli also have a bronchodilatory effect, i.e. help to dilate the bronchi and facilitating breathing. This property could be exploited by those who suffer from asthma, but research is still working on a pharmaceutical formulation which allows a mode of administration is different from the smoke because the latter would damage however the lungs. Glaucoma is a serious disturbance of the view is characterized by increased intraocular pressure, i.e. the inside of the eyes. For this disease the delta-9-THC seems to be useful as, in some cases, manages to reduce the internal pressure. To discover what was a US citizen, Dr Randall which has obtained by law to be able to cure with cannabis derivatives, opening the way to this therapy for this specific disorder of the view. His choice, in fact, has also confirmed in subsequent clinical studies. Already since 1985 the FDA (Food and Drug Administration), i.e. the American organization that controls the medicinal products in the USA has permitted the sale of a synthetic cannabinoid, i.e. produced in the laboratory, the dronabinol, able to counteract the nausea in who is subjected to chemotherapy. Recent studies have shown that a synthetic cannabinoid, dronabinol, even manages to whet the appetite, producing a significant weight gain in people with AIDS and affected by the so-called syndrome of decay. It was also presented a study that has clarified that the cannabis derivatives do not interfere with the antiviral drugs, i.e. those medicinal products used for fighting viruses such as HIV, which causes AIDS. The cannabidiol, i.e. a nonpsychoactive cannabinoid, also seems to have anticonvulsionanti properties, i.e. that help to combat the convulsions, one of the most common symptoms of epilepsy. Studies carried out on this disease, however, are still at the experimental stage, even if many patients who have voluntarily subjected to experiments, argue that the cannabidiol has helped them to overcome more easily the convulsions. This is also why the British medical association, one of the British authorities more authoritative in the health field, has recently recommended to further research on the action of this substance. The morbus Alzehimer, that of Parkinson, Huntington's Chorea, are all diseases as defined neurodegenerative diseases because they are caused by a degeneration of nerve cells. Recent studies conducted by international researchers have discovered that the cannabidiol, a component not psicoattivo of cannabis, helps protect the brain cells. The research, published in the scientific journal "Proceedings of National Academy", has demonstrated that the cannabidiol acts as an antioxidant, i.e. combats aging and death of neurons. Even if the studies are always at the experimental stage this discovery opens up new possibilities in the treatment of stroke and neurodegenerative disorders. The legislation in Italy and in the world adjusts the cannabis Recently, it has been discovered that in the human brain there are specific receptors for cannabinoids and that our body produces a substance (anandamide), able to interact with these receptors. This has allowed us to discover the existence of a true and proper "system endogenous cannabinoid", whose role within the organism is not yet entirely clear, but the study will allow us to understand the mechanisms that are at the base of the curative properties of cannabinoids. One of the main pharmacological actions of thc on the brain is to reduce the sensitivity to pain. This is very useful as an analgesic in respect of disorders such as migraine applicant or menstrual pain. Especially in the latter case the THC is suitable since it also has a function muscle relaxant, i.e. relax the muscles. In addition, the THC has an antiinflammatory action, then, is also useful in other types of pain such as those due to rheumatism. The muscle spasms are abnormal contractions of the muscles of the body, often due to serious diseases such as multiple sclerosis or Parkinson's disease. Cannabinoids have on the muscles a muscle relaxant and antispasmodic, consequently help decontrarre muscles, as demonstrated by a study published recently on the science journal 'Nature'. These specific curative properties you explain why the receptors for the cannabinoid CB1 are concentrated in the basal ganglia and cerebellum, i.e. in areas of the brain related to motor functions. Also for this reason, the Royal Pharmaceutical Society, an English association, has recently had the authorization by the British Government to proceed with further experimentation on 2000 sick people with multiple sclerosis, in order to be able to find the pharmaceutical formulation best to combat this serious disorder. In fact, one of the main issues to be solved for pharmaceutical administration of cannabis is just find the formulation more suitable for every type of disorder that is looking for a cure. In the case of muscle spasms, the road more followed from the scientific point of view is that of the aerosol. The cannabinoli also have a bronchodilatory effect, i.e. help to dilate the bronchi and facilitating breathing. This property could be exploited by those who suffer from asthma, but research is still working on a pharmaceutical formulation which allows a mode of administration is different from the smoke because the latter would damage however the lungs. Glaucoma is a serious disturbance of the view is characterized by increased intraocular pressure, i.e. the inside of the eyes. For this disease the delta-9-THC seems to be useful as, in some cases, manages to reduce the internal pressure. To discover what was a US citizen, Dr Randall which has obtained by law to be able to cure with cannabis derivatives, opening the way to this therapy for this specific disorder of the view. His choice, in fact, has also confirmed in subsequent clinical studies. Already since 1985 the FDA (Food and Drug Administration), i.e. the American organization that controls the medicinal products in the USA has permitted the sale of a synthetic cannabinoid, i.e. produced in the laboratory, the dronabinol, able to counteract the nausea in who is subjected to chemotherapy. Recent studies have shown that a synthetic cannabinoid, dronabinol, even manages to whet the appetite, producing a significant weight gain in people with AIDS and affected by the so-called syndrome of decay. It was also presented a study that has clarified that the cannabis derivatives do not interfere with the antiviral drugs, i.e. those medicinal products used for fighting viruses such as HIV, which causes AIDS. The cannabidiol, i.e. a nonpsychoactive cannabinoid, also seems to have anticonvulsionanti properties, i.e. that help to combat the convulsions, one of the most common symptoms of epilepsy. Studies carried out on this disease, however, are still at the experimental stage, even if many patients who have voluntarily subjected to experiments, argue that the cannabidiol has helped them to overcome more easily the convulsions. This is also why the British medical association, one of the British authorities more authoritative in the health field, has recently recommended to further research on the action of this substance. The morbus Alzehimer, that of Parkinson, Huntington's Chorea, are all diseases as defined neurodegenerative diseases because they are caused by a degeneration of nerve cells. Recent studies conducted by international researchers have discovered that the cannabidiol, a component not psicoattivo of cannabis, helps protect the brain cells. The research, published in the scientific journal "Proceedings of National Academy", has demonstrated that the cannabidiol acts as an antioxidant, i.e. combats aging and death of neurons. Even if the studies are always at the experimental stage this discovery opens up new possibilities in the treatment of stroke and neurodegenerative disorders. The legislation in Italy and in the world adjusts the cannabis Recently, it has been discovered that in the human brain there are specific receptors for cannabinoids and that our body produces a substance (anandamide), able to interact with these receptors. This has allowed us to discover the existence of a true and proper "system endogenous cannabinoid", whose role within the organism is not yet entirely clear, but the study will allow us to understand the mechanisms that are at the base of the curative properties of cannabinoids. One of the main pharmacological actions of thc on the brain is to reduce the sensitivity to pain. This is very useful as an analgesic in respect of disorders such as migraine applicant or menstrual pain. Especially in the latter case the THC is suitable since it also has a function muscle relaxant, i.e. relax the muscles. In addition, the THC has an antiinflammatory action, then, is also useful in other types of pain such as those due to rheumatism. The muscle spasms are abnormal contractions of the muscles of the body, often due to serious diseases such as multiple sclerosis or Parkinson's disease. Cannabinoids have on the muscles a muscle relaxant and antispasmodic, consequently help decontrarre muscles, as demonstrated by a study published recently on the science journal 'Nature'. These specific curative properties you explain why the receptors for the cannabinoid CB1 are concentrated in the basal ganglia and cerebellum, i.e. in areas of the brain related to motor functions. Also for this reason, the Royal Pharmaceutical Society, an English association, has recently had the authorization by the British Government to proceed with further experimentation on 2000 sick people with multiple sclerosis, in order to be able to find the pharmaceutical formulation best to combat this serious disorder. In fact, one of the main issues to be solved for pharmaceutical administration of cannabis is just find the formulation more suitable for every type of disorder that is looking for a cure. In the case of muscle spasms, the road more followed from the scientific point of view is that of the aerosol. The cannabinoli also have a bronchodilatory effect, i.e. help to dilate the bronchi and facilitating breathing. This property could be exploited by those who suffer from asthma, but research is still working on a pharmaceutical formulation which allows a mode of administration is different from the smoke because the latter would damage however the lungs. Glaucoma is a serious disturbance of the view is characterized by increased intraocular pressure, i.e. the inside of the eyes. For this disease the delta-9-THC seems to be useful as, in some cases, manages to reduce the internal pressure. To discover what was a US citizen, Dr Randall which has obtained by law to be able to cure with cannabis derivatives, opening the way to this therapy for this specific disorder of the view. His choice, in fact, has also confirmed in subsequent clinical studies. Already since 1985 the FDA (Food and Drug Administration), i.e. the American organization that controls the medicinal products in the USA has permitted the sale of a synthetic cannabinoid, i.e. produced in the laboratory, the dronabinol, able to counteract the nausea in who is subjected to chemotherapy. Recent studies have shown that a synthetic cannabinoid, dronabinol, even manages to whet the appetite, producing a significant weight gain in people with AIDS and affected by the so-called syndrome of decay. It was also presented a study that has clarified that the cannabis derivatives do not interfere with the antiviral drugs, i.e. those medicinal products used for fighting viruses such as HIV, which causes AIDS. The cannabidiol, i.e. a nonpsychoactive cannabinoid, also seems to have anticonvulsionanti properties, i.e. that help to combat the convulsions, one of the most common symptoms of epilepsy. Studies carried out on this disease, however, are still at the experimental stage, even if many patients who have voluntarily subjected to experiments, argue that the cannabidiol has helped them to overcome more easily the convulsions. This is also why the British medical association, one of the British authorities more authoritative in the health field, has recently recommended to further research on the action of this substance. The morbus Alzehimer, that of Parkinson, Huntington's Chorea, are all diseases as defined neurodegenerative diseases because they are caused by a degeneration of nerve cells. Recent studies conducted by international researchers have discovered that the cannabidiol, a component not psicoattivo of cannabis, helps protect the brain cells. The research, published in the scientific journal "Proceedings of National Academy", has demonstrated that the cannabidiol acts as an antioxidant, i.e. combats aging and death of neurons. Even if the studies are always at the experimental stage this discovery opens up new possibilities in the treatment of stroke and neurodegenerative disorders. The legislation in Italy and in the world adjusts the cannabis